 0 Table of Contents |
  1 Clinical Practice Guidelines (CPG) on EBMonFHIR |
  2 Profiles |
  3 Code Systems |
  4 Value Sets |
  5 Extensions |
  6 Examples |
  7 Downloads |
  8 History |
  9 Artifacts Summary |
   9.1 Cohorts |
   9.2 CPGComputablePlanDefinition |
   9.3 CPGRecommendationDefinition |
   9.4 CPGShareablePlanDefinition |
   9.5 CPGStrategyDefinition |
   9.6 Eligibility Criteria |
   9.7 Outcome Evidence |
   9.8 PICO Evidence Variable |
   9.9 Recommendation Action |
   9.10 Shareable PlanDefinition |
   9.11 Assessment Action |
   9.12 Body Positioning Action |
   9.13 Certainty of Evidence Rating |
   9.14 Clinical Practice Guideline |
   9.15 Drug Administration Action |
   9.16 Evidence Data Set |
   9.17 Evidence Synthesis Cohorts |
   9.18 Guideline Bundle |
   9.19 Guideline Citation |
   9.20 Intervention Definition |
   9.21 Net Effect Estimate |
   9.22 Outcome Definition |
   9.23 Outcome Evidence Synthesis |
   9.24 Procedure Action |
   9.25 Recommendation |
   9.26 Recommendation Citation |
   9.27 Recommendation Eligibility Criteria |
   9.28 Recommendation Justification |
   9.29 Recommendation Plan |
   9.30 Study Citation |
   9.31 Study Cohort |
   9.32 Study Eligibility Criteria |
   9.33 Study Outcome Evidence |
   9.34 Action Combination Method |
   9.35 ArtifactAssessment Publication Status |
   9.36 ArtifactAssessment Version |
   9.37 Characteristic Dosage |
   9.38 CQFM Artifact Comment |
   9.39 Dosage Condition |
   9.40 qualityOfEvidence |
   9.41 RelativeTime |
   9.42 strengthOfRecommendation |
   9.43 Action Combination Method |
   9.44 Action Selection Behavior Required |
   9.45 Allergic Disposition SCT |
   9.46 Assessment |
   9.47 Assessment Scales |
   9.48 Body Positioning SNOMED CT |
   9.49 Clinical Importance of Outcome |
   9.50 Cochrane PICO |
   9.51 Cochrane PICO Intervention |
   9.52 Cochrane PICO Outcome |
   9.53 Cochrane PICO Population |
   9.54 Drugs |
   9.55 Episode Of Care Type |
   9.56 Guideline Recommendation Status |
   9.57 Guideline Stage Classification |
   9.58 Mean Difference Type |
   9.59 Observations |
   9.60 Procedures |
   9.61 Radiologic Finding SCT |
   9.62 Rating Acceptability |
   9.63 Rating Benefit And Harms |
   9.64 Rating Certainty Of Evidence |
   9.65 Rating Concern Degree |
   9.66 Rating Consensus |
   9.67 Rating Equity |
   9.68 Rating Feasibility |
   9.69 Rating Preference And Values |
   9.70 Rating Resources |
   9.71 Rating Up Rating One Level |
   9.72 Rating Up Rating Two Levels |
   9.73 Recommendation Strength |
   9.74 Relative Effect Type |
   9.75 Substances SNOMED CT |
   9.76 VS MII ICU Code Observation Beatmung [LOINC] |
   9.77 Action Combination Method |
   9.78 CEOsys Code System |
   9.79 Clinical Importance of Outcome |
   9.80 Cochrane Core Ontology |
   9.81 Cochrane PICO Ontology |
   9.82 Evidence Certainty Rating |
   9.83 Evidence To Decision Certainty Rating |
   9.84 Evidence To Decision Certainty type |
   9.85 Guideline Stage Classification |
   9.86 KontaktArtDe |
   9.87 Recommendation Strength |
   9.88 SynthesisType |
   9.89 All-cause mortality |
   9.90 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V |
   9.91 Certainty of Evidence for outcome: mortality of Dexamethasone application |
   9.92 COVID19 Intensive Care Treatment Guideline |
   9.93 COVID19 Intensive Care Treatment Guideline |
   9.94 Dexamethasone Application |
   9.95 Dexamethasone Application |
   9.96 Dexamethasone Application (Intravenous) |
   9.97 Dexamethasone Application (Oral) |
   9.98 Dexamethasone for critically ill COVID-19 patients |
   9.99 Dexamethasone Recommendation |
   9.100 Example Assessment Action |
   9.101 Example Body Positioning Action |
   9.102 Example Certainty Of Evidence Rating |
   9.103 Example DrugAdministration Action |
   9.104 Example Evidence Data Set |
   9.105 Example Evidence Synthesis Cohorts |
   9.106 Example Guideline |
   9.107 Example Guideline Citation |
   9.108 Example Intervention |
   9.109 Example Net Effect Estimate |
   9.110 Example No DrugAdministration Action |
   9.111 Example Organization |
   9.112 Example Outcome |
   9.113 Example Outcome Evidence Synthesis |
   9.114 Example Procedure Action |
   9.115 Example Recommendation Citation |
   9.116 Example Recommendation Eligibility Criteria |
   9.117 Example Recommendation Eligibility Criteria |
   9.118 Example Recommendation Eligibility Criteria |
   9.119 Example Recommendation Justification |
   9.120 Example Recommendation plan |
   9.121 Example Study Citation |
   9.122 Example Study Cohort |
   9.123 Example Study Eligibility Criteria |
   9.124 Example Study Outcome Evidence |
   9.125 Guideline Recommendation Example |
   9.126 Mortality Outcome for Dexamethasone application |
   9.127 No Dexamethasone Application |
   9.128 No dexamethasone application for non-ventilated COVID-19 patients |
   9.129 NO Dexamethasone for moderately ill COVID-19 patients |
   9.130 Population: COVID19 Non-Ventilated |
   9.131 Population: COVID19 Ventilated |
   9.132 recommendation |
   9.133 Study cohort for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo) |
   9.134 Study eligibility criteria for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo) |
   9.135 Systemic corticosteroids for the treatment of COVID-19 |
   9.136 Therapy of hospitalized COVID-19 patients |